drugset / Trial / NCT04174339
PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is a single center, phase II study, to evaluate the effectiveness and safety of PD-1 Antibody(SHR-1210) Plus apatinib Combined With POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) , in the first-line treatment for patients with advanced/metastatic gastric cancer.
Timeline
- Start
- 2019-12-10
- Primary completion
- 2020-12-09
- Completion
- 2021-05-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Levoleucovorin | Unknown | 200 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | Other |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Other |